Rotavirus G1 strains represent the most common genotype that causes diarrhea in humans and has been incorporated into both, monovalent and multivalent, rotavirus licensed vaccines. The aim of this study was to determine the evolution profile of G1 rotaviruses in Córdoba, Argentina, over a 27-year period (1980-2006). Intragenotype diversity, represented by lineages within rotavirus circulating strains, was observed. Phylogenetic analysis of the VP7-gene of G1 rotavirus clinical strains showed the circulation of G1 lineage IV and V strains in the 1980s, and co-circulation of lineage I and II strains in the 1990s and 2000-2006. The distribution of G1 in lineages could be linked to multiple nucleotide substitutions distributed across lineages that did not correlate with the emergence of G1 antigenic variants. Moreover, temporal lineage distribution was not linked to significant changes in G1 prevalence. Therefore, the continuous and dominant circulation of G1 over time could not be related to the emergence of antigenic variants in the community. Continuous rotavirus surveillance is necessary to understand rotavirus evolution and to measure how genetic and antigenic changes might affect the effectiveness of vaccines in the future.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jmv.23462 | DOI Listing |
Front Cell Infect Microbiol
January 2025
Department of Haematology and Oncology, Shenzhen Children's Hospital, Shenzhen, China.
Background: Methicillin-resistant (MRSA) poses a significant challenge in clinical environments due to its resistance to standard antibiotics. Protein A (SpA), a crucial virulence factor of MRSA, undermines host immune responses, making it an attractive target for vaccine development. This study aimed to identify potential epitopes within SpA that could elicit robust immune responses, ultimately contributing to the combat against multidrug-resistant (MDR) MRSA.
View Article and Find Full Text PDFDiabetol Int
January 2025
Department of Endocrinology and Diabetes, NTT Medical Center Tokyo, 141-86255-9-22 Higashi-Gotanda, Shinagawa-ku, Tokyo Japan.
A 73-year-old Japanese woman was admitted to our hospital with anorexia, weight loss, and fever. A few weeks prior to admission, she became aware of anorexia. She was leukopenic, complement-depleted, and positive for antinuclear antibodies and anti-double stranded DNA antibodies.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Hematology, The Sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China.
CD7-targeted chimeric antigen receptor-T (CAR-T) cell therapy has shown great promise in the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL). In this study, we reported a case of a 34-year-old male patient with T-ALL who finally developed multi-line drug resistance and refractoriness after multiple lines of high-intensity chemotherapy. After physician evaluation, this patient received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Human natural killer (NK) cells can be sub-divided into two functional subsets but the clinical significance of these CD56 and CD56 NK cells in anti-tumour immunity remains largely unexplored. We determined the relative abundances of gene signatures for CD56 and CD56 NK cells along with 3 stromal and 18 other immune cell types in the patient tumour transcriptomes from the cancer genome atlas bladder cancer dataset (TCGA-BLCA). Using this computational approach, CD56 NK cells were predicted to be the more abundant tumour-infiltrating NK subset which was also associated with improved patient prognosis.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
B-cell acute lymphoblastic leukemia (B-ALL) with the fusion gene has a poor prognosis, and the mortality rate exceeds 90%, particularly in cases of extramedullary relapse (EMR). Herein, we present a case of a 46-year-old male patient who developed relapsed B-ALL with . The patient initially achieved a complete remission (CR) after induction therapy and underwent haploidentical hematopoietic stem cell transplantation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!